LNP023 (Age-Related Macular Degeneration) - Clinical Trial
What is the Purpose of this Study?
We are doing this study to find out if an investigational drug called JNJ-81201887 (the study drug) is a safe and effective option for people with geographic atrophy secondary to age-related macular degeneration.
Geographic Atrophy (GA) secondary to Age-related Macular Degeneration (AMD)
Who Can Participate in the Study?
Adults ages 50+ who:
- Are diagnosed with early or intermediate AMD
- Have not had eye surgery, including cataract surgery, within the last 3 months
- Have no active eye inflammation
For more information about who can be in this study, please contact the study team at DEC-RA@duke.edu.
What is Involved?
If you choose to join the study, you will:
- Get a random assignment (fair, equal chance) to 1 of 3 groups
-- One group will get a higher dose of the study drug
-- A second group will get a lower dose of the study drug
-- A third group will get a placebo (inactive substance)
- Visit our clinic at the Duke Eye Center up to 13 times.
- Keep in touch with the study team for about 19 months
At various visits, you will have blood draws, answer some questionnaires, and have eye exams and vision tests.
Study Details
